GlassScriptPhysician profile
Matthew L German
NPI 1073628871
$16,084.80
in general payments reported to CMS, 2019-2025
64 companies · $2,476 in 2025
The $2,476 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,638 · 2020: $1,705 · 2021: $1,893 · 2022: $3,078 · 2023: $2,091 · 2024: $2,204 · 2025: $2,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,760 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,759.85 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,103.75 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,274.33 | 2019-2025 | Sunlenca |
| Abbvie INC. | $1,695.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,084.24 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Janssen Biotech, INC. | $834.42 | 2019-2025 | Symtuza, Tremfya |
| Insmed, INC. | $385.85 | 2022-2025 | Arikayce |
| Aimmune Therapeutics, INC. | $342.06 | 2024-2025 | Vowst |
| Napo Pharmaceuticals INC | $329.21 | 2019-2024 | Mytesi |
| Theratechnologies INC. | $292.56 | 2020-2025 | Egrifta, Trogarzo |
| Pfizer INC. | $287.09 | 2019-2025 | |
| Ucb, INC. | $284.07 | 2019-2025 | Bimzelx, Cimzia |
| Shionogi INC | $281.25 | 2021-2022 | |
| Organogenesis INC. | $230.10 | 2019-2022 | |
| Amgen INC. | $227.62 | 2019-2025 | Tavneos |
| Emd Serono, INC. | $212.61 | 2020-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew German listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.